News
-
-
PRESS RELEASE
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing. The company specializes in acquiring stakes in European pharmaceutical subcontractors -
-
-
-
-
-
PRESS RELEASE
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC converts 4 convertible bonds in Oxurion leading to EUR 100,000 capital increase. Oxurion issues 6,230,425 new ordinary shares as part of the Capital Commitment with Atlas Special Opportunities, LLC -
-
PRESS RELEASE
Oxurion signs letter of intent for the contemplated acquisition of a CRO with strong complementarity to Axiodis
Oxurion NV announces the signing of a letter of intent to acquire a majority stake in a French Contract Research Organization (CRO) specialized in clinical development and regulatory affairs, enhancing its capabilities and services